
USPS crackdown on unregulated vapes adds to pressure on suppliers
Letters reviewed by Reuters show USPS revoked the mailing exception for Demand Vape, a New York-based distributor, after New York City's Law Department provided evidence the company had shipped products without required U.S. Food and Drug Administration (FDA) authorisation and in violation of a local flavour ban.
The July 15 letter informed Demand Vape that its local Buffalo Business Mail Entry office would no longer accept packages containing electronic nicotine delivery systems.
The move is expected to benefit tobacco giants like Altria and British American Tobacco, which have long fought the sale of unauthorised vapes, most of which originate from China. While the FDA has authorised just 39 e-cigarette products, the U.S. market remains flooded with unauthorised devices.
Demand Vape said it complies with the law and is contesting the revocation. "We reject any characterisation that paints Demand Vape as anything other than a transparent, lawful and reputable business," it said, describing the industry as operating in a "regulatory grey zone" with few authorised products meeting consumer demand.
USPS did not respond to a request for comment.
Since 2021, USPS has been barred from mailing vaping products directly to consumers internationally and in most other cases. Exceptions exist for domestic shipments between businesses, but these require a special "mailing exception" and compliance with all relevant laws. Other major carriers have similarly restricted service; FedEx does not ship vapes at all, and DHL only accepts approved business shipments.
USPS has also provided New York City's Law Department with a list of other companies holding mailing exceptions so the city can review whether they are complying with the law, Eric Proshansky, deputy chief of the division of affirmative litigation, told Reuters. This could further reduce shipping options for the unauthorised vape trade, forcing reliance on smaller, more expensive carriers.
British American Tobacco estimates the unauthorised U.S. vape market was worth about £6 billion (US$8.05 billion) last year. However, that market has been hit by a combination of new tariffs, seizures at U.S. ports, and a May crackdown in which the FDA sent warning letters to 24 distributors central to the supply chain.
The actions have left many vape store shelves empty, according to Tony Abboud, executive director of the Vapor Technology Association, whose members include Demand Vape. He said the USPS ban will deal another blow to the sector.
Court filings in a New York City lawsuit show that Demand Vape, one of the largest U.S. e-cigarette distributors, sells to roughly 5,000 retailers in 49 states. Evidence supplied by city attorneys to USPS included invoices documenting sales of unauthorised e-cigarettes, including brands the FDA has explicitly named as illegal.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
4 hours ago
- Globe and Mail
How major US stock indexes fared Wednesday, 8/13/2025
U.S. stocks notched some more records as a rally spurred by hopes for lower U.S. interest rates wrapped around the world. The S&P 500 rose 0.3% Wednesday. The Dow Jones Industrial Average climbed 1%, while the Nasdaq added 0.1% to its record set the day before. Treasury yields eased, as expectations reached a virtual consensus that the Federal Reserve will cut its main interest rate for the first time this year at its next meeting in September. On Wednesday: The S&P 500 rose 20.82 points, or 0.3%, to 6,466.58. The Dow Jones Industrial Average rose 463.66 points, or 1%, to 44,922.27. The Nasdaq composite rose 31.24 points, or 0.1%, to 21,713.14. The Russell 2000 index of smaller companies rose 45.28 points, or 2%, to 2,228.06. For the week: The S&P 500 is up 77.13 points, or 1.2%. The Dow is up 746.66 points, or 1.7%. The Nasdaq is up 263.12 points, or 1.2%. The Russell 2000 is up 109.64 points, or 4.9%. For the year: The S&P 500 is up 584.95 points, or 9.9%. The Dow is up 2,378.05 points, or 5.6%. The Nasdaq is up 2,402.35 points, or 12.4%. The Russell 2000 is up 97.90 points, or 4.4%.


Cision Canada
5 hours ago
- Cision Canada
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
SASKATOON, SK, Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000. Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000. The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025, and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025, in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.


CTV News
6 hours ago
- CTV News
CTV National News: Trump targeting semi-conductor industry
Watch U.S. President Donald Trump dropped another trade threat on his way to Alaska. Rachel Aiello has the details.